• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024

    5/9/24 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTN alert in real time by email

    CRANBURY, N.J., May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its third quarter fiscal year 2024 operating results on Wednesday, May 15, 2024, before the open of the U.S. financial markets.

    Palatin Technologies, Inc.

    Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 15, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.

    Schedule for the Operating Results Press Release, Conference Call / Audio Webcast



    Q3 Fiscal Year 2024 Results Press Release



    5/15/2024 at 7:30 a.m. ET

    Q3 Fiscal Year 2024 Conference Call-Live   

       US Toll Free Dial-In Number:

       International Dial-In Number:

       Participant Access Code:  



    5/15/2024 at 11:00 a.m. ET

    1-877-545-0523

    1-973-528-0016

    720217

    Q3 Fiscal Year 2024 Conference Call-Replay 

       US Toll Free Dial-In Number:   

       International Dial-In Number:   

       Participant Access Code:    

    5/15/2024-5/29/2024

    1-877-481-4010

    1-919-882-2331

    50601

    The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by clicking here.

    About Palatin

    Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-to-report-third-quarter-fiscal-year-2024-results-teleconference-and-webcast-to-be-held-on-may-15-2024-302140923.html

    SOURCE Palatin Technologies, Inc.

    Get the next $PTN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PTN

    DatePrice TargetRatingAnalyst
    11/24/2021$2.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PTN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Deveer Robert K Jr bought $10,180 worth of shares (100,000 units at $0.10), increasing direct ownership by 263% to 138,065 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      5/12/25 9:30:59 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive VP and CFO/COO Wills Stephen T sold $8,274 worth of shares (4,999 units at $1.66), decreasing direct ownership by 2% to 235,456 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      8/2/24 5:01:24 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive VP and CFO/COO Wills Stephen T covered exercise/tax liability with 16,171 shares, decreasing direct ownership by 6% to 240,455 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      7/31/24 4:31:03 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Deveer Robert K Jr bought $10,180 worth of shares (100,000 units at $0.10), increasing direct ownership by 263% to 138,065 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      5/12/25 9:30:59 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deveer Robert K Jr bought $12,703 worth of shares (6,000 units at $2.12), increasing direct ownership by 17% to 40,845 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      4/11/24 4:45:17 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Palatin Technologies with a new price target

      HC Wainwright & Co. reiterated coverage of Palatin Technologies with a rating of Buy and set a new price target of $5.00 from $2.00 previously

      11/24/21 6:07:03 AM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Palatin Technologies Inc.

      10-Q - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

      5/14/25 5:00:30 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by Palatin Technologies Inc.

      424B4 - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

      5/8/25 5:27:16 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palatin Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

      5/8/25 5:26:19 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care